SEC Filing Analysis: DAXOR CORP (DXR)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Medical Officer received a routine stock grant as part of a compensation plan, with no immediate market value.
• Market Impact: The transaction is not material and is expected to have a neutral impact on the stock.

Company Information

Field	Value
Company	DAXOR CORP
Ticker Symbol	DXR
CIK	0000027367
Market Cap	$60,000,000

Insider Information

Field	Value
Name	Jefferies John
CIK	0002086843
Title/Position	Chief Medical Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-11-12
Transaction Code	P (Purchase)
Security Type	Daxor Common Stock
Shares Involved	2,344
Price Per Share	$0.00
Total Value	$0
Shares Owned After	17,616
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	2,344
% of Shares Outstanding	0.048%
Post-Transaction Ownership	17,616 shares (0.36% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a $60 million market cap, this transaction has no monetary value and is therefore immaterial.
• Ownership Concentration: The insider's post-transaction ownership remains low at 0.36% of total shares outstanding.
• Dilution Impact: The grant of 2,344 shares represents a potential future dilution of approximately 0.05%, which is negligible for existing shareholders.
• Transaction Significance: The transaction is classified as 'Low' significance as its value is $0 and the shares involved are well below the 0.1% of shares outstanding threshold.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: This is a non-cash, routine compensatory grant to an executive. It does not signal a change in insider sentiment or company fundamentals.

Volume & Sentiment

• Expected Volume Impact: None. This is not an open-market transaction.
• Sentiment Indicator: Neutral. Standard executive compensation grants are not typically viewed as bullish or bearish signals.

Additional Context

Transaction Notes

• Special Circumstances: The filing's footnote clarifies: "2,344 shares granted vest on November 12, 2025." Although coded as 'P' (Purchase), the $0 price and footnote confirm this is a stock grant, likely of Restricted Stock Units (RSUs).